Literature DB >> 7601429

Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro.

J S McMillan1, T Shaw, P W Angus, S A Locarnini.   

Abstract

Hepatitis B virus (HBV) DNA-transfected hepatoma cells were incubated with the immunosuppressive agents prednisolone, azathioprine, and cyclosporin A (CsA) and the antiviral agents ganciclovir and foscarnet to investigate the effects of these compounds on HBV replication. Prednisolone and azathioprine increased intracellular viral DNA and RNA levels approximately twofold and fourfold, respectively. Treatment with CsA did not alter the levels of viral RNA or DNA. A combination of all three immunosuppressive agents increased the level of intracellular viral DNA eightfold, indicating an additive effect. Incubation of the cells in the presence of foscarnet decreased levels of both single-stranded and relaxed circular viral DNA, and in the presence of ganciclovir decreased the levels of relaxed circular viral DNA, predictable effects from their known mechanism of action. The stimulatory effect on viral replication induced by the combination of immunosuppressive agents was substantially inhibited by ganciclovir-foscarnet treatment. These observations could have implications for the management of recurrent HBV infection after liver transplantation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7601429

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  15 in total

1.  Significance testing of clinical data using virus dynamics models with a Markov chain Monte Carlo method: application to emergence of lamivudine-resistant hepatitis B virus.

Authors:  N J Burroughs; D Pillay; D Mutimer
Journal:  Proc Biol Sci       Date:  1999-12-07       Impact factor: 5.349

Review 2.  Treatment of follicular non-Hodgkin's lymphoma.

Authors:  David G Maloney
Journal:  Curr Hematol Rep       Date:  2005-01

3.  S-phase arrest after vincristine treatment may promote hepatitis B virus replication.

Authors:  Lei Xu; Zeng Tu; Ge Xu; Jie-Li Hu; Xue-Fei Cai; Xing-Xing Zhan; Yu-Wei Wang; Yuan Huang; Juan Chen; Ai-Long Huang
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 4.  Hepatic disorders in chronic kidney disease.

Authors:  Fabrizio Fabrizi; Piergiorgio Messa; Carlo Basile; Paul Martin
Journal:  Nat Rev Nephrol       Date:  2010-04-13       Impact factor: 28.314

5.  Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro.

Authors:  G Civitico; T Shaw; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

6.  Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis.

Authors:  C M Lo; S T Cheung; C L Lai; C L Liu; I O Ng; M F Yuen; S T Fan; J Wong
Journal:  Ann Surg       Date:  2001-02       Impact factor: 12.969

7.  Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression.

Authors:  Tara N Palmore; Neeral L Shah; Rohit Loomba; Brian B Borg; Uri Lopatin; Jordan J Feld; Farooq Khokhar; Glen Lutchman; David E Kleiner; Neal S Young; Richard Childs; A John Barrett; T Jake Liang; Jay H Hoofnagle; Theo Heller
Journal:  Clin Gastroenterol Hepatol       Date:  2009-07-01       Impact factor: 11.382

8.  Prophylaxis of hepatitis B infection in solid organ transplant recipients.

Authors:  Savio John; Karin L Andersson; Camille N Kotton; Martin Hertl; James F Markmann; A Benedict Cosimi; Raymond T Chung
Journal:  Therap Adv Gastroenterol       Date:  2013-07       Impact factor: 4.409

9.  Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation.

Authors:  Vignan Manne; Ruby M Allen; Sammy Saab
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-03

10.  Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.

Authors:  Ann W Walsh; David R Langley; Richard J Colonno; Daniel J Tenney
Journal:  PLoS One       Date:  2010-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.